Premium
Pure red cell aplasia in a prostate cancer patient treated with leuprolide acetate and chlormadinone acetate
Author(s) -
KOBAYASHI MINORU,
NUKUI AKINORI,
MORITA TATSUO
Publication year - 2005
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2005.01195.x
Subject(s) - medicine , chlormadinone acetate , prostate cancer , pure red cell aplasia , leuprorelin , urology , prostate , hormone , endocrinology , cancer , luteinizing hormone , anemia , population , gonadotropin releasing hormone , environmental health , health services
Pure red cell aplasia (PRCA) is characterized by anemia with reticulocytopenia but with normal leukocyte and platelet counts, and a bone marrow with a selective absence of erythroid precursor cells. Drug‐induced PRCA is a rare secondary form of PRCA, and is usually acute and fully reversible by the withdrawal of the causative drugs. We report a rare case of PRCA in a prostate cancer patient treated with combined androgen blockade (CAB) consisted of leuprolide acetate as a luteinizing hormone‐releasing hormone agonist and chlormadinone acetate as an antiandrogen. This case demonstrated that these drugs could be a cause of PRCA, and suggests that regular close monitoring for anemia is needed in prostate cancer patients treated with these drugs.